Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Intravenous Lidocaine on Normal Sensation and Pain in Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Adult Volunteers, age \>19 years~Exclusion Criteria:~* History of Substance Abuse~* Coronary Artery Disease (CAD): unstable~* Congestive Heart Failure (CHF): unstable~* Heart Arrhythmia: symptomatic~* Chronic Obstructive Pulmonary Disease (COPD)~* Lidocaine Allergy~* Diagnostic and Statistical Manual of Mental Disorders (Rev IV): Axis I: Common Axis I disorders include depression, anxiety disorders,bipolar disorder, ADHD, and schizophrenia. Axis II: borderline personality disorder, schizotypal personality disorder, antisocial personality disorder, and mild mental retardation.~* Presence of Contraindications for MRI~* Presence of electronically, magnetically, and mechanically activated implants~* Electronically, magnetically, and mechanically activated implants~* Ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators~* Cardiac pacemakers~* Metallic splinters in the eye~* Ferromagnetic haemostatic clips in the central nervous system (CNS)~* Claustrophobia~* Pregnancy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).